{"entity":{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","aka":["S1505"],"tldr":"SWOG S1505 gave people with operable pancreatic cancer three months of chemotherapy before and after surgery with one of the two modern regimens; about half were alive at two years with either, no better than the 40 percent threshold the trial set from adjuvant-only history, and a third of the patients enrolled turned out not to have resectable tumours on central review.","summary":"S1505 enrolled 147 patients between 2015 and 2018; 43 (29 percent) were ineligible at central radiology review because their disease exceeded resectability criteria, leaving 102 evaluable patients (55 on modified FOLFIRINOX, 47 on gemcitabine plus nab-paclitaxel). In each arm 84 to 85 percent completed preoperative chemotherapy, 73 and 70 percent underwent resection and 49 and 40 percent completed all treatment. Two-year overall survival was 47 percent (95 percent confidence interval 31 to 61) with modified FOLFIRINOX and 48 percent (31 to 63) with gemcitabine plus nab-paclitaxel, median overall survival 23.2 and 23.6 months, and neither arm's estimate exceeded the a priori 40 percent threshold; median disease-free survival after resection was 10.9 and 14.2 months. The trial showed perioperative chemotherapy is deliverable with high resection rates but did not show it improves survival over adjuvant treatment, and it exposed how often local teams over-call resectability, a quality-control problem carried into Alliance A021806.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02562716","url":"https://clinicaltrials.gov/study/NCT02562716"},{"label":"Sohal et al., SWOG S1505 (JAMA Oncology 2021)","url":"https://doi.org/10.1001/jamaoncol.2020.7328"}],"tags":[],"related":[],"cancers":["pancreatic","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["folfirinox","gemcitabine-nab-paclitaxel"],"companies":["swog"],"institutions":[],"pathways":[],"terms":["neoadjuvant-adjuvant","resectability"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02562716","phase":"2","setting":"Resectable pancreatic adenocarcinoma across the US National Clinical Trials Network: 12 weeks of modified FOLFIRINOX or gemcitabine plus nab-paclitaxel before and 12 weeks after surgery, a pick-the-winner randomised phase 2 with two-year overall survival as the primary endpoint","sponsor":"SWOG Cancer Research Network / National Cancer Institute","result":"Two-year overall survival 47 percent with perioperative modified FOLFIRINOX and 48 percent with perioperative gemcitabine plus nab-paclitaxel; neither exceeded the 40 percent historical threshold; median overall survival 23.2 and 23.6 months.","yearReported":2021,"enrolled":147,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 2 years (eligible patients)","primary":true,"unit":"%","arms":[{"name":"Perioperative mFOLFIRINOX","n":55,"value":47,"note":"95% CI 31 to 61"},{"name":"Perioperative gemcitabine + nab-paclitaxel","n":47,"value":48,"note":"95% CI 31 to 63"}],"source":"https://doi.org/10.1001/jamaoncol.2020.7328"}]},"route":"/trials/swog-s1505/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"term":[{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/"}],"trial":[{"id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/"}]}}